The Application Value of Spectral CT in the Accurate Staging of Liver Cancer

Launched by YUNNAN CANCER HOSPITAL · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a special type of imaging called Spectral CT to better understand and diagnose liver cancer. The goal is to see if this advanced imaging technique can provide clearer pictures of liver cancer, which may help doctors accurately determine the stage of the disease. By doing this, the researchers hope to improve treatment options and outcomes for patients with liver cancer.

To be eligible for this study, participants must be at least 18 years old, suspected of having liver cancer, and able to undergo a specific type of CT scan within a week before starting treatment. They also need to sign a consent form agreeing to take part in the trial. However, individuals with severe heart, lung, or kidney issues, those who are allergic to certain contrast agents used in scans, and pregnant or breastfeeding women are not eligible. If you choose to participate, you can expect to undergo a scan that helps doctors gather important information about your condition, which may lead to more personalized treatment plans.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
• • 2. Age \> 18 years.
• • 3. Patients suspected of having liver cancer.
• • 4. Patients who have signed the informed consent form.
• Exclusion Criteria:
• • 1. Severe cardiac, pulmonary, or renal insufficiency.
• • 2. Allergy to iodine-based contrast agents.
• • 3. Inability to cooperate with the CT examination.
• • 4. Poor image quality of the Quark Spectral CT scan.
• • 5. Women who are pregnant or breastfeeding.